Livagen
A Khavinson tetrapeptide proposed to support hepatic and lymphocyte function; reported to decondense chromatin in aged lymphocytes in in-vitro studies — Russian-language evidence, no Western replication.
A Khavinson-group short tetrapeptide (Lys-Glu-Asp-Ala) proposed to act on lymphoid and hepatic tissues, with in-vitro reports of chromatin decondensation and restoration of gene-expression patterns in aged lymphocytes.
Mechanism of action
Khavinson-group in-vitro studies report that Livagen causes chromatin decondensation in aged lymphocytes and restores transcriptional activity at heterochromatin regions that become silenced with age. The hypothesized in-vivo effect is restoration of immune-cell gene expression in aged animals.
Primary uses
- Investigational support for hepatic and immune aging (Russian literature)
- Research into chromatin aging
Typical dosing
Typical supplement protocols use 10 mg daily for 10–20 days.
Regulatory status
Not FDA-approved. Marketed in Russia as a bioregulator supplement.
References
- [pubmed] Khavinson VK, et al. "Activating effect of peptides Lys-Glu-Asp-Ala and Ala-Glu-Asp-Gly on chromatin of old lymphocytes." Bull Exp Biol Med, 2011;150:505-507.
- [review] Khavinson VK, Malinin VV. "Gerontological aspects of genome peptide regulation." Karger AG, Basel, 2005.
Related peptides
Guides & tools
This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.